Techniques to obtain large quantities of antigen-specific monoclonal antibodies, mAbs, were first established in the 1970s when Georges Köhler and César Milstein immortalized antibody-producing mouse B-lymphocytes by fusion with myeloma cells (http://www.whatisbiotechnology.org/exhibitions/milstein). Combined with the expression of human antibodies in transgenic animals, this technique allowed upon immunization the generation of highly specific fully human mAbs for therapeutic applications. Apart from being extremely beneficial, mAbs are a huge success commercially. However, despite cell fusion generating many useful mAbs questions have been asked about which types of cells are prone to fuse and whether other methods may identify a wider range of binders. The discovery that expression libraries, using E.coli or yeast, produced different specificities was intriguing and more recently Next Generation Sequencing has identified wide-ranging usage with highly diverse and unique repertoires. Another strategy is the combination of flow cytometry sorting of antigen-binding B-lymphocytes and single cell RT-PCR followed by re-expression, which has identified many high affinity mAbs.
Introduction
The expression of human Ig loci in transgenic animals was achieved by a combination of DNA transfer and integration strategies, knock-out approaches to silence interfering endogenous genes, and improving cloning, stability and manipulation of large DNA constructs accommodating ~1Mb Ig loci. 1 Over 25 years ago it was shown that a germline configured human IgH mini-locus could be stably integrated in the mouse genome, contributing faithfully to immune development by DNA rearrangement and producing human IgM. 2 These findings initiated many parallel transgenic approaches of integrating larger and more complete human IgH, Ig and Ig loci, initially in mice and later in cattle, rabbits and rats. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The human IgH variable region, shown in Figure 1 , has been as a whole or in large part linked with mouse, rat or human C-genes to generate a diverse human antibody repertoire. Importantly, knock-out approaches secured high expression of these transgenic loci.
13-15
Early on it became clear that cell-fusion methods established for immortalizing B cells from conventional laboratory mouse and rat strains 16, 17 were also applicable to generate high levels of specific human mAbs from transgenic lines. 2, 6, 7, 18, 19 However, to avoid hybrid cell instability and chromosomal loss it became advisable to identify antibody expression soon after fusion 20 , which could be done by RT-PCR analysis of individual clones obtained by limiting dilution. Antibody binding using supernatant was tested by ELISA. 21 In other early approaches V-domains could be displayed on the surface of filamentous bacteriophage, which allowed the isolation of rare antigen-binders. 22 Subsequent improvements in affinities have been obtained by chain shuffling 23 and joining of V H and V L domains. 24, 25 Human blood lymphocytes were frequently used to
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obtain V-gene libraries and initially there was no need to use transgenic animals. A similar strategy was established by Ribosome display systems. 26 Later, surface expression of ScFv by random combination of V H and V L in, both, phage 27, 28 and yeast 29, 30 permitted selection of high-affinity antigen binders directly and became an important tool to select human mAbs from transgenic animals. 31, 32 In other general selection approaches to establish single copy expression in mammalian cells virusmediated display 33 and, separately, homologous integration were successful. 34 Specific screening or enrichment of single B-lymphocytes from bone marrow, spleen or lymph nodes has also been used to identify antigen-specific binders. 35, 36 This technique often combines flow cytometry with single cell V H and V L cloning by RT-PCR. 37 Variations using magnetic beads for enrichment have also been described. 38 Another successful strategy, next generation sequencing, identified binders by sequence occurrence. 39, 40 For example, when the most abundant V H and V L sequences from bone marrow plasma cells of immunized mice were paired a large number of antigen-specific binders, some with nanomolar affinity, could be obtained.
41
Here a concise overview is presented of how high affinity mAbs can be isolated using cell fusion, display libraries, FACS and NGS approaches. Table 1 presents a summary of the technologies.
Hybridoma mAbs
Generating mAbs by hybridoma cell-fusion using spleen or lymph node cells is the most successful approach of deriving antigen-specific human antibodies from transgenic rodents. 1, 6, 8, 9 Previously, this generated fully human Abs 4, 42 whilst more recently chimeric products with human variable region but endogenous mouse or rat A C C E P T E D constant (C) region were obtained. 6, 8, 9 Expression of human V(D)Js linked to mouse or rat C has also increased antibody expression to near normal levels. Optimisation of the fusion process by using a range of myeloma partners has made this process highly successful and rapid immunization schemes using transgenic rats produced diverse binders easily by this technology. 6, 19 .
The great manufacturability of animal derived antibodies has resulted in more FDA approvals compared to display antibodies selected from human cells ( Table 2) . products can be obtained jointly has also been described; the aim was to speed up the process and include cloning and re-expression as Fab. 66 In this VH-VL linkage-cloning,
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termed Symplex PCR, FACS sorted individual human plasma cells produced near 1%
antigen-specific binders and with adaptation this method could be used to amplify sorted B cells from transgenic rodents.
Next generation sequencing and identification of binders
Major improvements in sequence processing in the last few years has established a very efficient high-throughput technology termed Next Generation Sequencing (NGS). This has allowed the discovery of near-complete immune repertoires. 67 68 As explained in To overcome the problem with correct VH-VL pairing of NGS sequences 2 strategies have been tried; both finding antigen-specific antibodies with nanomolar affinity. In one approach single-cell emulsion droplets provided natively paired and subsequently correctly linked VH and VL sequences and in the other strategy abundant VH and VL sequences were paired based on their frequencies revealed by NGS. 41, 70 In both approaches distinct human or mouse B cell populations were enriched by FACS.
Nevertheless, avoiding selection or enrichment procedures prior to NGS is also possible 
Summary
In conclusion, numerous antibody screening libraries in different formats have been instrumental in identifying antigen-specific mAbs. Important technical advances have improved the success rate, increasing the number of specific sequences found ( Figure   2 ). For conventional antibodies in (H-L) n format, single cell strategies facilitated correct pairing while high-throughput sequencing and bioinformatics analyses can predict correct V H -V L combinations. These strategies identified many immensely beneficial high affinity human anti-human mAbs from transgenic rodents; some are already in the clinic others in late phase trials 1, 44 , with the majority for cancer treatment, followed by treatment of autoimmunity, musculoskeletal problems and infectious diseases. Table 2 provides a comprehensive list of therapeutic mAbs in clinical use but it comes at a high price. 72 Recently in the UK the use of Nivolumab, trade name Opdivo, received extensive attention when described as a life-extending drug that was too expensive (http://news.sky.com/story/aa-gills-last-article-reveals-life-extending-drug-was-tooexpensive-10692057).
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As significant improvements have been made recently with the derivation of rats and mice expressing high levels of human antibodies in human V(D)J rodent C chimeric form, cost reductions are highly likely. It is also interesting to speculate how high affinity mAbs may be isolated in the next few years. A clue may be provided by an increased use of sophisticated computation models so that in future it may be possible to identify specific binders directly from NGS libraries by occurrence and CDR pattern. 73, 74 Thus, to rapidly obtain specific human antibodies from transgenic rodents a combination of the above described strategies may be advantageous; first enrichment of antigen-binding B cells which is then followed by high-throughput sequencing and usage of analyses programmes to identify high affinity binders. 
26

